The blockade of MCP-1/CCR2 signaling for inhibiting pro-inflammatory macrophage infiltration could be a promising therapeutic approach for obesity and diabetes (143, 144). Here, CCL2 is linked to obesity due to melanocortin 4 receptor deficiency.